Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province,Spain |
| |
| Institution: | 1. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain;2. Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, C/ Universitat de Girona 10, 17003 Girona, Spain;3. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Carrer del Sol 15, 17004 Girona, Spain;4. Radiation Oncology Service, Josep Trueta University Hospital, Catalan Institute of Oncology, Avinguda de França, S/N, 17007 Girona, Spain;5. Hematological Laboratory Service, Germans Trias i Pujol University Hospital, Catalan Institute of Oncology, Josep Carreras Leukaemia Research Institute, Ctra. de Can Ruti Camí de les Escoles S/N, 8916 Badalona, Spain;6. Hematological Service, Josep Trueta University Hospital, Catalan Institute of Oncology, Avinguda de França, S/N, 17007 Girona, Spain;1. Department of Ophthalmology, Central Hospital of Linyi, Yishui, Shandong, 276400, China;2. Department of Ophthalmology, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China;1. Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, #10-01, 117549, Singapore;2. National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore;3. National Registry of Diseases Office, Health Promotion Board, 3 Second Hospital Avenue, 168937, Singapore;4. Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, 308433, Singapore;1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada;2. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy;3. Vita-Salute San Raffaele University, Milan, Italy;4. Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;5. Department of Urology, European Institute of Oncology, Milan, Italy;6. Division of Medical Oncology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada;7. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany;8. Department of Urology, Medical University of Vienna, Vienna, Austria;9. Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada;10. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA;1. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;2. Department of Pediatrics, Amsterdam UMC, Amsterdam, The Netherlands;3. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands;4. Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands;1. Servicio de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas, España;2. Servicio de Dermatología, Hospital Universitari Bellvitge, L’ Hospitalet de Llobregat, Barcelona, España;3. Servicio de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España;4. Servicio de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz Tenerife, España;5. Servicio de Dermatología, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, España;6. Servicio de Dermatología, Hospital de Cruces, Baracaldo, Vizcaya, España;7. Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España;8. Servicio de Dermatología, Hospital Clínico de Valencia, Valencia, España;9. Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España;10. Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España;11. Servicio de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, España;12. Servicio de Dermatología, Hospital Universitario Príncipe de Asturias., Alcalá de Henares, Madrid, España;13. Servicio de Dermatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España;14. Servicio de Dermatología, Hospital Universitario Dr. Peset, Valencia, España;15. Servicio de Dermatología, Hospital Universitario Infanta Cristina, Parla, Madrid, España;p. Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, España;q. Servicio de Dermatología, Hospital Universitario de Basurto, Bilbao, Vizcaya, España;r. Servicio de Dermatología, Hospital Universitario de Henares, Coslada, Madrid, España;s. Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, España;t. Servicio de Dermatología, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España;u. Servicio de Dermatología, Hospital Universitario 12 de Octubre, Institute i+12, Medical School. Universidad Complutense, ONCOCIBER, Madrid, España;1. Service d’hématologie clinique, Hôpital de Roubaix, 11–17, boulevard Lacordaire, 59056 Roubaix, France;2. Université de Lille, CHU de Lille, Institut Pasteur de Lille, EA 4483, IMPECS, IMPact of Environmental Chemicals on human health, 59000 Lille, France;3. CHU de Lille, Pôle de Santé Publique, 59000 Lille, France;4. Institut Pasteur de Lille, 59000 Lille, France;5. Registre général des cancers de Lille et de sa région, C2RC, 59037 Lille, France;6. Conseil Départemental du Pas-de-Calais, 62018 Arras, France;7. Université de Lille, EA 2694 – Santé Publique : épidémiologie et qualité des soins, 59000 Lille, France |
| |
| Abstract: | BackgroundThe aim of this study was to describe incidence patterns of lymphoid neoplasms in the Girona province (Spain) (1996–2015), and to predict the number of cases in Spain during 2020.MethodsData were extracted from the Girona cancer registry. Incident cases were classified using the ICD-O-3, third revision, and grouped according to the WHO 2008 classification scheme. Age-adjusted incidence rates to the European standard population (ASRE) were estimated and incidence trends were modeled using Joinpoint.Results4367 lymphoid neoplasms were diagnosed in the Girona province. The ASRE for overall lymphoma was 37.1 (95% CI: 36.0; 38.2), with a marked male predominance in almost all subtypes. During 1996–2015, incidence trends remained stable for broader lymphoma categories. According to our predictions, 17,950 new cases of LNs will be diagnosed in Spain in 2020.ConclusionsThis ‘real-world’ data will provide valuable information to better inform etiological hypotheses and plan future health-care services. |
| |
| Keywords: | Lymphoid neoplasms Population-based Incidence WHO 2008 Spain |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
